Enclomiphene clinical trials: what the evidence really shows

Last updated 2026-07-27

What is enclomiphene and how is it different from clomiphene?

Enclomiphene is one of two isomers that make up clomiphene citrate, the older fertility drug most people know as Clomid. Clomiphene citrate is actually a mixture of two molecules, enclomiphene (the trans-isomer) and zuclomiphene (the cis-isomer), combined in roughly a 62:38 ratio ^[1]. These two isomers don't behave the same way in the body. Enclomiphene is the shorter-acting, estrogen-receptor-antagonist component. It's the one doing most of the work at the hypothalamus, blocking estrogen feedback so the brain thinks estrogen is low and ramps up GnRH, then LH and FSH, then testosterone. Zuclomiphene has a much longer half-life (some estimates put it at several weeks with repeated dosing) and has weaker estrogenic activity that some researchers think blunts the benefit and adds side effects over time ^[2]. The pitch behind isolating enclomiphene was simple: keep the isomer that raises testosterone through the hypothalamic-pituitary-gonadal axis, drop the one that may just add estrogenic baggage. That idea is exactly what the Androxal development program tried to prove in the clinic, and it's why you'll see enclomiphene described as a selective estrogen receptor modulator, or SERM, rather than a testosterone product itself. If you're new to dosing questions once you understand the mechanism, the Enclomiphene Direct dosage guide covers how this translates into actual prescribing ranges.

Did enclomiphene ever complete FDA-approved clinical trials?

Yes, it went through real trials, but no, it never reached approval. Enclomiphene citrate was developed under the brand name Androxal by Repros Therapeutics, and it went through Phase 2 and Phase 3 trials aimed at treating secondary hypogonadism in men, meaning low testosterone caused by pituitary or hypothalamic signaling problems rather than testicular failure. The Phase 3 program included studies comparing Androxal against topical testosterone gel and placebo. Data presented from these trials showed Androxal restored testosterone to normal range in a majority of hypogonadal men while testosterone gel suppressed sperm counts and LH/FSH levels, exactly the contrast the sponsor was trying to demonstrate ^[3]. Repros Therapeutics submitted a New Drug Application to the FDA, but the agency did not approve it. Public FDA correspondence and company statements pointed to concerns the agency wanted addressed, including additional safety and efficacy data, before it would consider approval again ^[4]. Repros discontinued the Androxal program afterward, and no other sponsor has since taken enclomiphene through a completed FDA approval pathway. This matters practically. There is no FDA-approved enclomiphene product on the market today. What clinics prescribe and what pharmacies dispense is compounded enclomiphene, made by state-licensed compounding pharmacies under a prescription, not a version that went through the FDA's standard manufacturing and labeling review ^[5]. That's a real regulatory distinction, not a technicality, and it shapes everything from quality control to what claims a provider can legally make about it.

What did the Phase 3 Androxal trials actually measure?

The core Phase 3 comparison looked at three things: testosterone normalization, sperm count and semen parameters, and hormone levels (LH and FSH) as a proxy for whether the hypothalamic-pituitary-gonadal axis stayed intact. These were studied head-to-head against topical testosterone gel in men with secondary hypogonadism. Across the published and presented data, Androxal normalized serum testosterone in the majority of treated men, performing comparably to testosterone gel on that single measure ^[3]. Where it separated from testosterone gel was on sperm count: men on testosterone gel showed significant declines in sperm concentration, consistent with what's well documented for exogenous testosterone therapy generally, while men on Androxal maintained sperm counts closer to baseline ^[3]. LH and FSH told a similar story. Exogenous testosterone suppresses LH and FSH because the pituitary senses adequate androgen and stops signaling the testes. Androxal, by blocking estrogen receptor feedback rather than supplying testosterone directly, kept LH and FSH from crashing the way they do on TRT ^[3]. That's the mechanistic reason enclomiphene tends to preserve testicular size and spermatogenesis where injectable or gel testosterone often doesn't. What the trials did not establish, and this is worth being honest about, is a direct pregnancy or live-birth outcome. The endpoints were hormonal and semen-parameter surrogates, not fertility outcomes in couples trying to conceive. That gap in the data still exists today across the broader enclomiphene literature.

Does enclomiphene really preserve fertility better than TRT?

The mechanistic and short-term data say yes, on the markers that matter for fertility (LH, FSH, sperm parameters, testicular volume). Nobody has a large randomized trial proving enclomiphene users go on to father children at a specific higher rate than TRT users, because that trial hasn't been run. Exogenous testosterone (injections, gels, pellets) supplies the body with external androgen. The hypothalamus and pituitary sense that androgen level and shut down GnRH, LH, and FSH signaling almost entirely. Without LH stimulating the testes directly, intratesticular testosterone drops (even while blood testosterone rises), sperm production falls, and testes often shrink over months. This is well established in reproductive endocrinology literature and is the standard explanation given to men considering TRT while family planning ^[6]. Enclomiphene works upstream instead. By blocking estrogen receptors in the hypothalamus, it increases the body's own GnRH pulse, which increases LH and FSH, which increases the testes' own testosterone production alongside continued sperm production. A 2013 study in the Journal of Sexual Medicine comparing enclomiphene to testosterone gel in hypogonadal men found enclomiphene increased testosterone while maintaining or even modestly raising sperm concentration, in contrast to gel's suppressive effect ^[7]. A smaller but frequently cited body of clinical experience (case series, small prospective cohorts, and clinician-reported outcomes from reproductive urology practices) supports using enclomiphene or its parent compound clomiphene citrate off-label in men who want testosterone correction without sacrificing fertility, and it's a common first-line approach among reproductive urologists for exactly this reason . But 'preserves the fertility-relevant hormones and semen parameters' is not the same claim as 'guarantees you or your partner will conceive.' Male fertility depends on more than LH, FSH, and sperm count; sperm motility, morphology, female partner factors, and age all matter, and no enclomiphene trial has isolated pregnancy rate as a primary endpoint.

How does enclomiphene compare to clomiphene citrate in the trial data?

Because enclomiphene is literally one component of clomiphene citrate, comparative studies exist looking at whether isolating it improves on the whole mixture. The general finding: enclomiphene appears to raise testosterone at least as effectively as clomiphene citrate, with a shorter half-life and less accumulation of the zuclomiphene isomer that's suspected (though not conclusively proven) to carry more estrogenic side-effect risk with chronic use ^[2]. A randomized crossover study published in the Journal of Sexual Medicine (Kim et al., referenced in enclomiphene development literature) and subsequent Repros-sponsored trials found comparable testosterone increases between enclomiphene and clomiphene citrate, without a clear superiority signal strong enough on its own to win FDA approval ^[3][7]. That's an important nuance: enclomiphene's theoretical cleaner profile hasn't been proven in head-to-head trials to translate into meaningfully better patient outcomes, just a different pharmacokinetic profile. | Feature | Enclomiphene | Clomiphene citrate | Exogenous TRT |

What did the FDA actually say about approving enclomiphene?

The FDA's public-facing record on Androxal is limited mostly to what Repros Therapeutics itself disclosed in SEC filings and press releases, since the agency doesn't typically publish detailed rejection letters. What is documented: Repros received a Complete Response Letter type outcome, and subsequent public statements referenced the FDA wanting more data, including cardiovascular safety data, before reconsidering the application ^[4]. This is consistent with a broader FDA posture on testosterone-related products generally. In 2015 the FDA required updated labeling on all approved testosterone products, citing possible cardiovascular risk signals and requiring clearer language that these drugs are approved for men with hypogonadism due to specific medical conditions, not normal aging . It's reasonable to think similar cardiovascular safety scrutiny applied to enclomiphene's approval package, though the agency has not published that reasoning in a citable public document specific to Androxal. The practical upshot for anyone researching enclomiphene today: there is no FDA-approved enclomiphene drug product, full stop. Compounded enclomiphene is legal to prescribe and dispense under state pharmacy compounding law and Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows compounding pharmacies to prepare patient-specific prescriptions, but compounded drugs are not FDA-approved and don't go through the same manufacturing, labeling, or efficacy review ^[5]. A prescriber can still legally and appropriately prescribe it off-label using the clinical judgment supported by the Phase 2/3 data described above, and many reproductive urologists and men's health clinics do exactly that.

Is compounded enclomiphene the same thing that was studied in the trials?

Close, but not identical, and the distinction matters more than most sourcing pages admit. The Androxal trials used a specific formulation manufactured under investigational new drug (IND) protocols with controlled dosing, purity testing, and standardized delivery. Compounded enclomiphene comes from a licensed compounding pharmacy, typically as capsules or a reconstituted solution, made to a prescriber's specifications. The active molecule is the same enclomiphene citrate studied in the Phase 3 program. What can differ is formulation consistency, since compounding pharmacies aren't required to prove bioequivalence to a reference product (there isn't an approved reference product to compare to) the way generic manufacturers must. This is why using a reputable, PCAB-accredited or state board-inspected compounding pharmacy, and working with a provider who reviews your labs before and during treatment, actually matters here, more than it would with a standard FDA-approved generic. Enclomiphene Direct connects patients with providers who review labs and prescribe compounded enclomiphene through licensed U.S. pharmacy partners; it's worth understanding that this model, prescription plus compounding pharmacy fulfillment, is the only legal way to access enclomiphene in the U.S. right now, since there's no over-the-counter or FDA-approved retail version. For people actually starting therapy, the practical questions shift from trial data to logistics: how to reconstitute it if it arrives as a lyophilized vial, how to use the dosage calculator to match a prescribed mg dose to volume, and general injection technique if your specific formulation is injectable rather than oral (most compounded enclomiphene is oral capsules, but formulations vary by pharmacy).

What do we still not know from the clinical trial data?

Several real gaps remain, and a good clinician or a good article says so plainly instead of glossing over them. First, long-term cardiovascular safety data is thin. The FDA's reported concern about wanting more safety data before approving Androxal suggests the agency saw the existing dataset as insufficient for a chronic-use approval, and no large post-marketing surveillance exists since it was never marketed ^[4]. Second, actual pregnancy and live-birth rates were never a primary trial endpoint. Everything favorable that's said about enclomiphene and fertility rests on surrogate markers, LH, FSH, sperm concentration, testicular volume, not on couples' real-world conception outcomes. That's a meaningful evidence gap for anyone using enclomiphene specifically because they're trying to conceive soon. Third, most published enclomiphene studies are short-duration (weeks to a few months) rather than multi-year. How testosterone, sperm parameters, and any side effects behave over 2, 5, or 10 years of continuous use isn't well characterized in controlled trials, though clinical experience with the mechanistically similar clomiphene citrate spans decades of off-label male use. Fourth, dosing standardization is still evolving in practice. Clinical trial doses for Androxal generally ranged around 12.5 mg to 25 mg daily, but compounded prescribing today varies by provider and patient response, and there's no single FDA-labeled dosing chart to defer to. If you're mapping trial doses to a real prescription, the Enclomiphene Direct dosage page and cycle length guide reflect current clinical practice patterns rather than an approved label, because no approved label exists.

What are the known side effects seen in enclomiphene trials?

Across the Androxal Phase 2/3 program and subsequent smaller studies, the most commonly reported side effects were relatively mild and included headache, mood changes, and occasional visual disturbances, similar to the side-effect profile long associated with clomiphene citrate in men ^[3][7]. Estrogen-related side effects (gynecomastia, water retention) appear less frequent than with the mixed clomiphene compound, plausibly because enclomiphene carries less of the estrogenic zuclomiphene load, though this hasn't been proven in a dedicated head-to-head safety trial. Visual disturbances are a known class effect for SERMs generally and are called out specifically in clomiphene citrate's FDA label as a reason to discontinue use if they occur ^[1]. Anyone starting enclomiphene should know this is a documented, if uncommon, effect worth reporting to a prescriber immediately. Mood effects, including irritability or low mood in a subset of users, come up often enough in both trial data and clinical practice reports that it's worth setting expectations rather than being surprised by it.

Who were the trial subjects, and does that match who's using it today?

The Androxal Phase 3 trials enrolled adult men diagnosed with secondary hypogonadism, meaning low testosterone with low or inappropriately normal LH/FSH, generally confirmed hypogonadal on repeat morning testosterone testing per standard endocrine criteria ^[3]. This is a narrower population than 'men who want higher testosterone.' Today's compounded enclomiphene users are a broader group. Some genuinely fit that secondary hypogonadism profile. Others are using it as a TRT alternative primarily because they want to preserve fertility while addressing borderline-low testosterone, a legitimate off-label extrapolation from the trial population but not literally the same population studied. Others still are using it for fertility support in the context of a couple actively trying to conceive, again extrapolating from surrogate marker data rather than a trial designed around that specific goal. None of this makes off-label use inappropriate. Off-label prescribing based on strong mechanistic and surrogate-marker evidence is common and legal in U.S. medicine. It does mean the confidence level you should assign to 'this will work for me' should track how closely your situation matches the actual trial population: confirmed secondary hypogonadism with normal baseline pituitary function.

Bottom line: what does the evidence actually support?

Enclomiphene has genuine Phase 2 and Phase 3 human trial data behind it, more than theory or bodybuilding forum experience. That data supports the core claim: it raises testosterone in men with secondary hypogonadism while preserving LH, FSH, sperm concentration, and testicular size substantially better than exogenous testosterone therapy does ^[3][7]. What the evidence does not support is FDA approval (it never got there, and Repros discontinued the program after the FDA wanted more data) ^[4], guaranteed fertility or pregnancy outcomes (no trial measured that directly), or long-term safety certainty beyond a few months of controlled study duration. If you're weighing enclomiphene against TRT specifically because you want to keep the option of having children, the mechanistic and short-term clinical data genuinely favor enclomiphene on that specific axis. Just go in knowing you're relying on a compounded product prescribed off-label, backed by real but incomplete trial data, dispensed through a compounding pharmacy rather than a name-brand FDA-approved bottle. That's a reasonable, evidence-informed choice for a lot of men. It's just not the same thing as 'FDA-approved fertility-safe testosterone treatment,' and nobody should market it to you that way.

Frequently asked questions

Is enclomiphene FDA approved?

No. Enclomiphene was developed as Androxal by Repros Therapeutics and went through Phase 2 and Phase 3 trials, but the FDA did not approve it, reportedly requesting additional safety data. Repros later discontinued the program. Today's enclomiphene is compounded by licensed pharmacies under a prescription, not sold as an FDA-approved branded or generic drug.

What's the difference between enclomiphene and clomiphene?

Clomiphene citrate is a mixture of two isomers, enclomiphene (trans) and zuclomiphene (cis), roughly in a 62:38 ratio. Enclomiphene is the isomer thought to drive most of the testosterone-boosting, estrogen-receptor-blocking effect, with a shorter half-life. Zuclomiphene lingers longer and is suspected, though not proven, to contribute more to estrogenic side effects.

Does enclomiphene preserve fertility better than TRT?

On the surrogate markers studied, LH, FSH, sperm concentration, and testicular size, yes, enclomiphene tends to preserve them where exogenous TRT suppresses them. No large trial has measured actual pregnancy or live-birth rates for enclomiphene users, so 'preserves fertility markers' is accurate; 'guarantees fertility' is not supported by current data.

What happened to the Androxal enclomiphene program?

Repros Therapeutics completed Phase 2 and Phase 3 trials for Androxal (enclomiphene citrate) in secondary hypogonadism and submitted an application to the FDA. The FDA did not approve it, and public reporting indicates the agency wanted more safety data. Repros discontinued further development, and no other company has since completed an FDA approval pathway for enclomiphene.

Can women take enclomiphene?

Enclomiphene itself has been studied mainly in men; clomiphene citrate (the full isomer mixture, including enclomiphene) is FDA-approved specifically for inducing ovulation in women with certain infertility conditions. Enclomiphene alone is not FDA-approved for any use in women, and compounded enclomiphene marketed to men is not typically prescribed for female fertility.

Is compounded enclomiphene legal?

Yes. Licensed pharmacies can legally compound enclomiphene for an individual patient under a valid prescription, under Section 503A of the federal Food, Drug, and Cosmetic Act and state pharmacy board rules. It's not FDA-approved as a finished drug product, but prescribing and compounding it off-label is legal medical practice in the U.S.

What dose of enclomiphene was used in clinical trials?

Androxal Phase 3 trials generally tested doses in the range of about 12.5 mg to 25 mg daily. Compounded prescriptions today vary by provider, patient labs, and response, since there's no FDA-approved label to standardize against. See the enclomiphene dosage guide for how clinics translate trial-era doses into current prescribing.

Does enclomiphene shrink the testicles like TRT can?

Trial and mechanistic data suggest generally no, or much less than exogenous TRT. Because enclomiphene raises LH and FSH rather than suppressing them, the testes keep receiving their own stimulation signal and tend to maintain size, unlike on injectable or gel testosterone, where LH suppression often leads to testicular shrinkage over months.

What are the most common enclomiphene side effects?

Trial data shows headache, mood changes, and occasional visual disturbances as the most reported side effects, similar to clomiphene citrate's known profile. Estrogen-related effects like gynecomastia appear less common than with full clomiphene citrate, though no dedicated head-to-head safety trial has confirmed that difference conclusively.

Why isn't enclomiphene sold as a brand-name drug if it works?

It has real supportive trial data, but the FDA didn't consider that data sufficient for approval, reportedly wanting more long-term safety information, particularly around cardiovascular risk, a concern the agency has flagged for testosterone-related therapies generally. The sponsor, Repros Therapeutics, discontinued the program rather than run additional trials.

How do I know if I'm a good candidate for enclomiphene based on the trial population?

The Androxal trials enrolled men with confirmed secondary hypogonadism, meaning low testosterone alongside low or inappropriately normal LH/FSH on repeat testing. If your labs match that pattern, you're closer to the studied population. If you have primary testicular failure or normal-range testosterone, the trial data applies less directly to you.

Can enclomiphene help with fertility if I'm actively trying to conceive?

It may help by supporting LH, FSH, and sperm parameters better than TRT would, but no trial has measured pregnancy or live-birth rates directly, so no provider should promise conception outcomes. If fertility is your primary near-term goal, work with a reproductive urologist who can evaluate semen parameters directly alongside hormone therapy.

Sources

1. FDA, Clomid (clomiphene citrate) prescribing information: Clomiphene citrate composition, approved indication, and visual disturbance warning
2. Kim et al., pharmacokinetics of clomiphene isomers, cited in enclomiphene development literature: Enclomiphene and zuclomiphene have different half-lives and estrogenic activity
3. Wiehle et al., Journal of Sexual Medicine, enclomiphene vs testosterone gel in secondary hypogonadism: Phase 3 comparative data on testosterone normalization, LH/FSH, and sperm parameters
4. Repros Therapeutics SEC filing / press release on Androxal FDA response: FDA did not approve Androxal and requested additional data
5. Endocrine Society, Testosterone Therapy in Men with Hypogonadism Clinical Practice Guideline: Exogenous testosterone suppresses LH/FSH and intratesticular testosterone, reducing spermatogenesis
6. Kaminetsky et al., Journal of Sexual Medicine, enclomiphene citrate effects on sperm concentration: Enclomiphene maintained or increased sperm concentration versus testosterone gel
7. Wheeler et al., Translational Andrology and Urology, clomiphene citrate use in male hypogonadism: Clinical use pattern of clomiphene/enclomiphene as fertility-sparing alternative to TRT among reproductive urologists